SAN DIEGO, December 22, 2015 – eFFECTOR Therapeutics, a biopharmaceutical company developing translation regulators for the treatment of cancer, today announced that it has received $40 million in a Series B financing following the advancement of its lead program toward clinical trials. The financing was led by Altitude Life Science Ventures and joined by AbbVie Biotech Ventures and BioMed Ventures. […]
SAN DIEGO, Dec. 15, 2015 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that Alana McNulty has joined eFFECTOR as its full-time chief financial officer.
The poster titled “eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)” was presented by Kevin R. Webster, Ph.D., on December 5, 2015 at the 57th Annual 2015 American Society of Hematology (ASH) meeting in Orlando, FL.
SAN DIEGO, June 19, 2015 – eFFECTOR Therapeutics co-founder Davide Ruggero, Ph.D., has published ground-breaking research in the preeminent biomedical journal Cell which demonstrates preclinical promise for a cancer treatment approach that’s centered on selectively regulating the cell’s protein synthesis process, known as translation.
San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing. eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer.